Fiche centre
City of Hope
Duarte — United States
Essais liés9clinical trials
VilleDuartelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT00981578
Essais cliniques associés
9| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| ExAblate MRgFUS | Cancer | Non applicable | NCT01833806 | A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain | COMPLETED |
| INBRX-106 - Hexavalent OX40 agonist antibody | Cancer | Phase 1/2 | NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | RECRUITING |
| ZL-1310 | Cancer | Phase 1 | NCT06179069 | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | RECRUITING |
| KITE-363 | Lupus | Phase 1 | NCT07038447 | A Study of KITE-363 in Participants With Refractory Autoimmune Diseases | ENROLLING_BY_INVITATION |
| ExAblate 2100 | Cancer | Non applicable | NCT00981578 | ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain | TERMINATED |
| SC291 | SEP | Phase 1 | NCT05878184 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | ACTIVE_NOT_RECRUITING |
| cemacabtagene ansegedleucel | SEP | Phase 2 | NCT06500273 | ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | RECRUITING |
| Rituximab | SEP | Phase 1 | NCT03636503 | Rituximab + Immunotherapy in Follicular Lymphoma | TERMINATED |
| Sacituzumab govitecan-hziy | Cancer | Phase 3 | NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | ACTIVE_NOT_RECRUITING |